In the present investigation, we found that SLC39A14 silencing may promote erastin-induced ferroptosis in glioma by modulating the levels of MDA, Fe2+, GSH, GPX4, NRF2, and SLC7A11, which may further inhibit the progression of gliomas. The gene discussed is SLC39A14; the disease is central nervous system cancer.